Modifying peripheral blood myeloid cells for immunotherapy in vivo
Research type
Research Study
Full title
A recent breakthrough in the battle against cancer has been the field of immunotherapy: using a patient’s immune system to destroy tumours. CAR-T therapy is one such approach, with T cells isolated from patients, modified to express anti-cancer molecules, then re-administered. We will explore the use of a different immune cell compartment, the myeloid cell family, as an alternative cell for cancer therapy and evaluate its potential to be modified to exert anti-cancer activities using in vitro experimental systems and and murine models
IRAS ID
254183
Contact name
Leonard W. Seymour
Contact email
Sponsor organisation
MacrophOx Ltd.
Duration of Study in the UK
2 years, 3 months, 4 days
Research summary
A recent breakthrough in the battle against cancer has been the field of immunotherapy: using a patient’s immune system to destroy tumours. CAR-T therapy is one such approach, with T cells isolated from patients, modified them with anti-cancer molecules, then re-administered. We will explore the use of a different immune cell compartment, the myeloid cell family, as an alternative cell for cancer therapy and evaluate its potential to be modified to exert anti-cancer activities using in vivo models.
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
18/YH/0468
Date of REC Opinion
13 Dec 2018
REC opinion
Unfavourable Opinion